The BioOne Board of Directors has appointed Lauren Kane as the next President/CEO of BioOne, beginning January 1, 2022. She succeeds Susan Skomal, Ph.D. who has announced her retirement after 16 years at BioOne’s helm.
MD Anderson and Schrödinger, Inc. announced a two-year strategic research collaboration to optimize the development of Schrödinger's WEE1 inhibitor program, designed to target the WEE1 kinase.
A new international trial to assess whether high doses of the antiparasitic drug nitazoxanide could help treat patients with COVID-19 has begun in South Africa. Researchers at the University of Liverpool and Liverpool School of Tropical Medicine (LSTM) are leading the trial as part of the ground-breaking COVID-19 drug testing platform, AGILE.
TU Graz, the University of Leoben, the Austrian Fire Brigade Association and ILF Consulting Engineers have investigated the effects of e-vehicle fires in tunnel systems. The results are reassuring for passenger cars, but not for commercial vehicles. For the latter, as well as for fires in multistorey car parks, further investigations are urgently needed.
- Austrian Research Promotion Agency (FFG), ASFINAG, Austrian Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation, and Technology (BMK)
A new data source to help scientists better understand the ionosphere and its potential impact on communications and positioning, navigation, and timing—an essential utility for many critical operations—is now available to the public.
NRG Oncology activated the highly anticipated colorectal cancer prevention trial, FORTE, NRG-CC005. FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps) is a large, randomized trial of surveillance colonoscopy for participants with a first-time diagnosis of 1 or 2 small benign polyps, called adenomas.
Illinois Institute of Technology Professor Phil Troyk has been appointed co-convenor of the IEC working group setting standards on Human Augmentation, which includes brain-machine interfaces, enhanced strength, enhanced sensing, embodied computing, ambient intelligence and biohacking.
A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR’s Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less aggressive (‘epithelial’) to being more aggressive (‘mesenchymal’), and vice versa. By converting highly aggressive cancer cells to become less aggressive, tumours are primed to respond better to chemotherapy, which works to eliminate cancer cells. This discovery has led to the launch of a three-year long human clinical trial, BEXMET (Bexarotene-induced Mesenchymal-Epithelial Transition), to investigate this unconventional approach to treating TNBC.
Lithium-ion batteries are common but can pose safety problems. Solid-state batteries are smaller, safer and store more energy. Scientists at Argonne are accelerating a new generation of better batteries.
The Alliance Foundation Trials, LLC (AFT), in partnership with Genentech, a member of the Roche Group, today announced the launch of the first gynecological oncology study in the AFT portfolio - AFT-50 EndoMAP [A phase IB/II umbrella study for patients with recurrent or persistent endometrial cancer]. The AFT-50 EndoMAP study will evaluate the efficacy and safety of targeted agents paired with immunotherapy with atezolizumab for patients with recurrent or persistent endometrial cancer. The study is launching with three study cohorts; additional cohorts to be treated with or without atezolizumab are under development.
Recent studies by the University of Kentucky's HEALing Communities Study (Helping to End Addiction Long-term) researchers show a notable rise in opioid overdose death rates among non-Hispanic Black individuals.